July 2023 - Page 2 of 2

FridayJul 14, 2023 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11% Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries Bioavailability is the ability of…

TuesdayJul 11, 2023 9:00 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

Lexaria just released its mid-year update, highlighting its key milestones so far and its objectives going forward, summarized in a recent Zacks update Of note was the company’s most ambitious clinical study yet, HYPER-H21-4, along with its growing patent portfolio that now sees six additional patents awarded across Australia, Japan, the U.S., and Canada so far in 2023 The company also noted its $2 million capital raise back in May, a strong indicator of shareholders’ confidence in the brand, and its efforts to grow its operations Lexaria looks to build on the momentum gathered so far, and its management is…

MondayJul 10, 2023 10:30 am

D-Wave Quantum Inc. (NYSE: QBTS) Technology Ready to Answer Call of Proposed Legislation for Near-Term Quantum Applications to Solve Optimization Problems

Legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing – some within 24 months or less for developing and deploying demos, proofs of concepts, and pilots Global government spending on quantum application development is expected to reach $36 billion during 2023 D-Wave offers quantum solutions to help government and public sector develop applications that can solve important optimization problems Recent legislation presented to Congress calls for the United States government to develop and adopt near-term quantum computing applications to solve complex public sector optimization problems, which could include electrical grid resilience, optimization…

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

ThursdayJul 06, 2023 9:00 am

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3 Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023 Genprex is combining its lead product candidate, REQORSA, with…

WednesdayJul 05, 2023 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Contract Renewal Indicates Company’s Success in Supporting International Transports

Freight Technologies (aka Fr8Tech) has developed a technology solution that uses machine learning and artificial intelligence (“AI”) to help shipping and freighting companies optimize product transports and avoid costly errors Fr8Tech recently announced that one of its top clients, multinational insulation manufacturing company K-FLEX de México SA de CV, renewed its contract for using Fr8Tech’s core tech solution, Fr8App K-FLEX cited Fr8App’s benefits to the company during the difficult COVID-19 pandemic period and beyond as K-FLEX expanded its operations and approaches $1 billion in annual revenues Fr8Tech is continuing to expand its technology frontiers with the establishment of a dedicated…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Month: July 2023

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

Lexaria Bioscience Corp. (NASDAQ: LEXX) – A Zacks Update

D-Wave Quantum Inc. (NYSE: QBTS) Technology Ready to Answer Call of Proposed Legislation for Near-Term Quantum Applications to Solve Optimization Problems

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Freight Technologies Inc. (NASDAQ: FRGT) Contract Renewal Indicates Company’s Success in Supporting International Transports

TinyGems

Quote / Research

Site Search